Treatment with Imaavy (nipocalimab-aahu) has led to sustained disease control for up to 1.5 years among adolescents with generalized myasthenia gravis (gMG), according to data from the long-term extension (LTE) part of a Phase 2/3 clinical trial. The study, called Vibrance-MG (NCT05265273), is now evaluating Imaavy’s safety…
News
Weekly treatment with gefurulimab —an investigational C5 inhibitor from Alexion, Astrazeneca Rare Disease, that’s designed to be self-administered — led to early and sustained reductions in disease severity for adults with generalized myasthenia gravis (gMG), according to top-line data from a Phase 3 clinical trial. The findings…
Vyvgart (efgartigimod alfa-fcab) led to significant and clinically meaningful reductions in disease severity among adults with generalized myasthenia gravis (gMG) who test negative for disease-causing antibodies targeting the acetylcholine receptor (AChR). Notably, benefits were seen across different subgroups of anti-AChR antibody-negative patients, who are also known as having…
Vyvgart (efgartigimod alfa-fcab), currently approved in the U.S. for treating certain adults with generalized myasthenia gravis (gMG), safely eased disease severity in adolescents with the disease, according to new data from a Phase 2/3 trial. Called ADAPT JR (NCT04833894), the study is still recruiting younger children,…
Facing the daily challenges of myasthenia gravis (MG) requires more than medication: It demands diligent self-management, including careful attention to stress and rest, and a cautious navigation of the digital world. Those are the main takeaways from the webinar, “Pushing Back at MG: From Getting Informed to…
People who recover from myasthenia gravis (MG) after long-term treatment have higher numbers of certain subsets of monocytes — a type of immune cell — and lower numbers of others, a small study in China found. “Consistent with previous studies, our study further validated that dysregulation of immune cells,…
Vyvgart (efgartigamod) rapidly eased symptoms of generalized myasthenia gravis (gMG) and prevented complications before, during, and after surgery in a 23-year-old woman, a case study reported. The woman required surgery to remove a mass in her abdominal cavity while also experiencing a gMG flare-up. Clinicians successfully removed the…
Rystiggo (rozanolixizumab-noli) can be safely self-administered by people with myasthenia gravis (MG), according to data from a Phase 3 clinical trial. Based on these findings, at-home administration of Rystiggo was authorized earlier in 2025 in Japan and Europe. The work was funded by UCB, the company that sells Rystiggo.
Anxiety related to COVID-19 is more prevalent among people with myasthenia gravis (MG) than among the general population, a study in Germany shows. For individuals with MG, the most pronounced cause of such anxiety was the fear patients experienced about the consequences of a COVID-19 infection on their health.
People with myasthenia gravis (MG) have higher levels of a protein called neurofilament light chain (NfL) in their blood, especially if their symptoms are severe or start later in life, a recent study found. This means that NfL could help doctors track how the disease develops and decide on…
Recent Posts
- MG age and MG stage echo what patients have been saying all along
- Women with MG have higher risk of complications during pregnancy
- This year, I’m pushing boundaries in how I live with MG
- Early rituximab treatment may improve long-term outcomes in gMG
- Vyvgart plus low-dose steroids is safer treatment for severe gMG: Study